Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Achieve Life Sciences (ACHV – Research Report) today and set a price target of $35.00. The company’s shares opened today at $4.85.
Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Achieve Life Sciences, and Viridian Therapeutics. According to TipRanks, Higgins has an average return of 4.6% and a 34.21% success rate on recommended stocks.
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $24.67.
See Insiders’ Hot Stocks on TipRanks >>
ACHV market cap is currently $102.6M and has a P/E ratio of -1.56.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
- Achieve Life Sciences announces presentation of ORCA-V1 trial results
- Achieve Life Sciences (ACHV) Q2 Earnings Cheat Sheet
- Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
